IM Recombinant Ricin Toxin Vaccine (RVEc) — 3-Dose Primary Series With Boost

Ricin Poisoning Clinical Trial

Official title:
Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster

Status Withdrawn

Clinical Trial Summary

This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10, 50, or 75 μg IM. This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02385825
Study type	Interventional
Source	U.S. Army Medical Research and Development Command
Contact
Status	Withdrawn
Phase	Phase 1
Start date	April 2016
Completion date	December 2017

View Details

See also
	Status	Clinical Trial	Phase
	Withdrawn	`NCT02386150` - ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ — 3-Dose Primary Series With Boost	Phase 1
	Completed	`NCT01846104` - Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults	Phase 1